Jeffrey Miskoff
Pulmonary Disease · Manasquan, NJNPI 1245232032
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $158,258 of the $175,650 with a category attached, or 90.1%. 31 manufacturers reported payments, led by Grifols USA, LLC at 36.3% of the total. Reporting peaked in 2019 at $59,417 and has fallen 99.8% since, to $99 in 2024. Among pulmonary disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 529 payments — averaging $332.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$64K
- AstraZeneca$45K
- Mallinckrodt Hospital Products Inc.$27K
- Mallinckrodt Enterprises LLC$17K
- GSK$16K
- Pfizer$2K
- plus $5K from 25 others
Across 11 payments — averaging $4798.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$30K
- Boehringer Ingelheim$14K
- Sanofi US Services Inc.$8K
What the payments were for
- Consulting fees$1,5251%
- Speaking & faculty fees$158,25890%
- Travel & lodging$6,2264%
- Food & beverage$9,4435%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 112 | $63,678 |
| AstraZeneca | 119 | $45,246 |
| Mallinckrodt Hospital Products Inc. | 25 | $27,323 |
| Mallinckrodt Enterprises LLC | 9 | $16,790 |
| GSK | 56 | $15,620 |
| Pfizer | 2 | $2,483 |
| Insmed, Inc. | 14 | $1,158 |
| Rigel Pharmaceuticals, Inc. | 1 | $600 |
| Philips North America LLC | 38 | $431 |
| Jazz Pharmaceuticals Inc. | 26 | $400 |
| Boehringer Ingelheim | 30 | $286 |
| Actelion Pharmaceuticals US, Inc. | 19 | $272 |
| Mylan Specialty L.p. | 19 | $260 |
| Regeneron Healthcare Solutions, Inc. | 11 | $258 |
| La Jolla Pharmaceutical Company | 2 | $161 |
| Sunovion Pharmaceuticals Inc. | 9 | $113 |
| ANI Pharmaceuticals, Inc. | 1 | $101 |
| Electromed, Inc. | 9 | $81 |
| Sanofi | 5 | $69 |
| Genentech USA, Inc. | 4 | $54 |
| Teva Pharmaceuticals USA, Inc. | 4 | $50 |
| Harmony Biosciences LLC | 2 | $33 |
| Apria Healthcare LLC | 2 | $28 |
| Shire North American Group Inc | 2 | $27 |
| Eisai Inc. | 2 | $27 |
| Mirati Therapeutics, Inc. | 1 | $24 |
| Portola Pharmaceuticals, LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Amgen | 1 | $13 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$43,644
- ACTHAR$43,421
- Prolastin-C Liquid$40,667
- Prolastin-C$21,581
- NUCALA$15,120
- ELIQUIS$2,483
- Arikayce$925
- Tavalisse$600
- TEZSPIRE$354
- SYMBICORT$232
- BREZTRI$194
- DUPIXENT$130
- GIAPREZA$113
- BREZTRI AEROSPHERE$102
- PURIFIED CORTROPHIN GEL$101
How this compares
$175,650 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $6,760 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $5,096 |
| Potassium Chloride | 12 | $2,412 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,061 |
| Lansoprazole | 24 | $387 |
| Torsemide | 21 | $126 |
| Ciprofloxacin Hcl | 17 | $110 |
| Alprazolam | 11 | $90 |
| Mupirocin | 11 | $65 |
| Atorvastatin Calcium | 17 | $28 |
| Metoprolol Tartrate | 20 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,483 | $6,76012 claims |
| AstraZenecaBevespi Aerosphere | $45,246 | $5,09612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Manasquan
- Paul FriedmanManasquan$58K
- Gustavo DelaluzManasquan$13K
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.